相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events
E. Karlsson et al.
EUROPEAN JOURNAL OF CANCER (2014)
Variation in detection of ductal carcinoma in situ during screening mammography: A survey within the International Cancer Screening Network
Elsebeth Lynge et al.
EUROPEAN JOURNAL OF CANCER (2014)
International variation in management of screen-detected ductal carcinoma in situ of the breast
Antonio Ponti et al.
EUROPEAN JOURNAL OF CANCER (2014)
Molecular profiling of breast ductal carcinoma in-situ
Emmanuel Agosto-Arroyo et al.
PATHOLOGY (2014)
Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ
Laura G. Estevez et al.
BREAST CANCER RESEARCH (2014)
Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype
M. Lazzeroni et al.
BRITISH JOURNAL OF CANCER (2013)
HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ
E. Rakovitch et al.
BRITISH JOURNAL OF CANCER (2012)
Biologic and Immunologic Effects of Preoperative Trastuzumab for Ductal Carcinoma In Situ of the Breast
Henry M. Kuerer et al.
CANCER (2011)
Lapatinib Activity in Premalignant Lesions and HER-2-Positive Cancer of the Breast in a Randomized, Placebo-Controlled Presurgical Trial
Andrea DeCensi et al.
CANCER PREVENTION RESEARCH (2011)
Targeting the HER/EGFR/ErbB Family to Prevent Breast Cancer
Louise R. Howe et al.
CANCER PREVENTION RESEARCH (2011)
The Significance of HER-2/neu Receptor Positivity and Immunophenotype in Ductal Carcinoma In Situ with Early Invasive Disease
Shuko Harada et al.
JOURNAL OF SURGICAL ONCOLOGY (2011)
HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component
Ning Liao et al.
PATHOLOGY RESEARCH AND PRACTICE (2011)
Current perspectives of treatment of ductal carcinoma in situ
Laura G. Estevez et al.
CANCER TREATMENT REVIEWS (2010)
Biomarker Expression and Risk of Subsequent Tumors After Initial Ductal Carcinoma In Situ Diagnosis
Karla Kerlikowske et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
HER-2/neu Overexpression as a Predictor for the Transition from In situ to Invasive Breast Cancer
Robert E. Roses et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2009)
Current management of DCIS: a review
Neill Patani et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Predicting relapse in ductal carcinoma in situ patients: an analysis of biologic markers with long-term follow-up
Tina J. Hieken et al.
AMERICAN JOURNAL OF SURGERY (2007)
MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study
Christiane K. Kuhl et al.
LANCET (2007)
Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue
K. Lindemann et al.
HISTOPATHOLOGY (2007)
The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer
R. L. Dillon et al.
ONCOGENE (2007)
HER-2/neu status is a determinant of mammary aromatase activity in vivo:: Evidence for a cyclooxygenase-2-dependent mechanism
Kotha Subbaramaiah et al.
CANCER RESEARCH (2006)
Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status
M Dowsett et al.
ANNALS OF ONCOLOGY (2006)
Effects of HER2 overexpression on cell signaling networks governing proliferation and migration
Alejandro Wolf-Yadlin et al.
MOLECULAR SYSTEMS BIOLOGY (2006)
The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast
EK Latta et al.
MODERN PATHOLOGY (2002)
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer:: Evidence from a phase III randomized trial
MJ Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
